AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05211362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sticky Bone and Repeated Injectable PRF (iPRF)
Description: The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, then the defect was filled with xenograft mixed with IPRF, Finally, the flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
Study NCT05211362 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone substitute
Description: The surgical treatment phase was initiated only if the subjects had a full-mouth dental plaque score of less than one and a test site plaque score of 0. Following mucoperiosteal flap reflection for one tooth on either side of the defect, all granulation tissue was removed from the defects by means of Gracey 7/8 metal curettes, and root surfaces were scaled and planed using hand and ultrasonic instruments, bone graft substitute was heavily condensed into the intra bony defects. The flap was replaced and closed with crossed horizontal and vertical internal mattress sutures.
Study NCT05762198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rezūm
Description: In the REZUM arm, water vapour treatment is performed for all subjects under local anaesthesia.
Study NCT05762198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: In the TURP arm, all men will receive TURP operation under general or spinal anaesthesia
Study NCT05306275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Factor XIIa antagonist monoclonal antibody for subcutaneous use
Study NCT04843137 — intervention group
Intervention type: DEVICE
Intervention: Cervical Transcutaneous Electrical Spinal Cord Stimulation
Description: Surface electrodes are placed over the cervical spinal cord. Constant current is delivery through these electrodes. Stimulation frequency and electrode configuration are manipulated, and outcome measures are recorded.
Study NCT06530056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costovertebral Mobilization+Conventional Therapy
Description: Patient would receive costovertebral mobilization in side lying position for left 10th to 6th, in sitting position for right 10th to 2nd rib and in supine lying position for 1st rib.~Conventional Therapy:~Hot pack 10 mints, Posture corrective exercises, Breathing exercises Frequency; 4 times/week for 3 weeks
Study NCT06530056 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Therapy
Description: Electrotherapy:~• Hot Pack 10 minutes~Posture Corrective Exercises:~* Thoracic Rotation 10 rep/session~* Thoracic extension 10 rep/session~* Scapular retraction 5 rep/session~* Deep neck flexor Isometric 5 rep/session~Deep Breathing Exercises:~• Pursed lip breathing 10 repetition in one session
Study NCT06355388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tVNS
Description: As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus, and a 10-minute stimulation will be initiated with a pulse width of 200 μs, a frequency of 30 Hz, and an intensity of one mA lower than the patient's sensitivity threshold.~As fort he mid-term phase, a device will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session.
Study NCT06355388 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tVNS
Description: As for the short-term phase, the ear clip of the Parasym device (Parasym, London, United Kingdom), containing the stimulation electrode, will be positioned at the level of the patient's tragus for 10-minute but no current will be delivered.~As fort he mid-term phase, a device (configured to withhold power delivery) will be given to the patient, which will be instructed to position the ear clip of the device at the level of the tragus and to set stimulation parameters as established in the laboratory (see above). Each patient will be asked to undergo at least one hour daily stimulation for a period of 4 weeks, reporting on a diary the timing and details of the each session.
Study NCT05207306 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of interfascial plane block
Description: In the M-TAPA group, after finding the right 10th costal cartilage using ultrasound guidance, a anesthesiologist inject 0.375% ropivacaine 15ml into the lower aspect of the chondrium. Perform left M-TAPA in the same way.~In the subcostal TAPB group, a anesthesiologist inject 0.375% ropivacaine 15ml into end of right rectus abdominis muscle using ultrasound guidance. Perform left subcostal TAPB in the same way.
Study NCT06417346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic TEP Repair
Description: Laparoscopic TEP Repair performed
Study NCT06417346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Technique (Lichtenstein)
Description: Open Technique (Lichtenstein) performed
Study NCT05188430 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device (Kaptufat®)
Description: 140 mg chitosan, 460 mg cellulose and 35.384 mg ascorbic acid for 1 tablet~Oral administration: 3 tablets twice a day before the main meals
Study NCT05188430 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 3 tablets twice a day before the main meals
Study NCT05309616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taltz
Description: Participants will receive160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2,4,6,8,10,12 and then 80 mg every 4 weeks
Study NCT06173505 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vudalimab + Carboplatin + Pemetrexed
Description: Vudalimab intravenous + carboplatin intravenous + pemetrexed intravenous
Study NCT06173505 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab + Carboplatin + Pemetrexed
Description: Pembrolizumab intravenous + carboplatin intravenous + pemetrexed intravenous
Study NCT05991427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine (Adenovirus Vector) (ChAdOx1-VZV)
Description: 2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Study NCT06270355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk based screening
Description: Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
Study NCT06270355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Risk based screening
Description: Women randomised to the individualised screening arm and judged to be at high risk will be invited to a contrast enhanced mammography and a mammography after 12 months. The intervention is thus a different selection of women compared to what is done today.
Study NCT05991427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
Description: 2 doses of Shingrix vaccine on Day 0 and Month 4
Study NCT05991427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-VZV
Description: 2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Study NCT05415852 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser
Study NCT05380674 — intervention group
Intervention type: BEHAVIORAL
Intervention: The short questionnaire of healthy habits
Description: collects sociodemographic data, weight, height, and physical activity, self-reported.
Study NCT04702217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: A 16-week training program consisting of 2-3 visits per week, and 60 minutes per visit. The program will be done as group exercise under supervision from physiotherapists with special interest in POTS.
Study NCT04809389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DelNS1-nCoV-RBD LAIV
Description: Genetically engineered live attenuated influenza virus to express the receptor binding domain of SARS-CoV-2's spike protein for triggering human body's immune responses against SARS-CoV-2
Study NCT04809389 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: 0.9% NaCl solution
Study NCT06224621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endocardial Septal Radiofrequency Ablation
Description: Percutaneous Endocardial Septal Radiofrequency Ablation (PESA) is used to ablatethe hypertrophied septum of obstructive hypertrophic cardiomyopathy (oHCM) patients.
Study NCT04719741 — intervention group
Intervention type: OTHER
Intervention: Parallel Assignment
Description: Prospective, Triple blinded, randomized, controlled trial
Study NCT05037786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infographic
Description: Key themes related to pain and injury in elite players based on previous studies presented using an A3 infographic
Study NCT05037786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Powerpoint
Description: Key themes related to pain and injury in elite players based on previous studies presented using a Powerpoint
Study NCT05748327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcasite restorative material
Description: Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), conditioning with primer, mixing alcasite capsula, place restoration, polymerizing and finishing
Study NCT05748327 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill glass hybrid restorative material
Description: Cavity preparation, pulp protection (if necessary), placing matrix/ interdental wedge (if necessary), mixing bulk fill glass hybrid capsula, conditioning, place restoration, apply coating, polymerizing and finishing
Study NCT04520776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAGUERA®C Cervical Disc Prosthesis
Description: surgery
Study NCT04520776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobi-C® Cervical Disc
Description: surgery
Study NCT05842967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: 120-µg
Study NCT05842967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04878497 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Initiation of warfarin, identified using prescription fill in pharmacy claims
Study NCT04878497 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Initiation of dabigatran, identified using prescription fill in pharmacy claims
Study NCT04878497 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Initiation of rivaroxaban, identified using prescription fill in pharmacy claims
Study NCT04878497 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Initiation of apixaban, identified using prescription fill in pharmacy claims
Study NCT04878497 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: Initiation of edoxaban, identified using prescription fill in pharmacy claims
Study NCT06049953 — intervention group
Intervention type: DRUG
Intervention: Antipsychotics
Description: Antipsychotic medications are widely prescribed for severe mental illness such as affective and non-affective psychosis, mood stabilization, and augmentation of unipolar depression.
Study NCT06049953 — intervention group
Intervention type: DRUG
Intervention: Non-antipsychotic medication
Description: Psychotropic medications are typically prescribed to manage symptoms of anxiety, depression, psychological distress, and/or insomnia.
Study NCT06049953 — intervention group
Intervention type: OTHER
Intervention: No Medication
Description: Non-psychotropic medications
Study NCT05279508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make My Day - stroke prevention program
Description: A stroke prevention program within primary healthcare
Study NCT05991427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: 2 doses of Shingrix vaccine on Day 0 and Month 4
Study NCT05991427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IH ChAdOx1-VZV
Description: 2 doses of ChAdOX1-VZV vaccine on Day 0 and Month 4
Study NCT05991427 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IH saline
Description: 2 doses of saline on Day 0 and Month 4
Study NCT04372875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHS-derived CDS
Description: This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
Study NCT06019910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snus with or without tobacco
Description: At baseline, participants have used the intervention daily for at least 30 days. They will then cease usage of the intervention abruptly. After 3 weeks, they may continue to abstain from the intervention or relapse at their own discretion.
Study NCT06396663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Opioid de-escalation
Description: Option 1: 10% - 50% decrease/day until opioids discontinued (≤ 10 days). For Fentanyl patches in decrements of 12 mcg/hr.~Option 2: Stop all opioid medication completely
Study NCT06396663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gradual Opioid de-escalation
Description: Option 1: 20% - 50% decrease/weekly until opioids discontinued Option 2: 10% - 20% decrease/weekly until 30 mg daily. Then reduce by 5% - 10% everyday.
Study NCT06396663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of opioids
Description: Continue on opioids and review in 1 weeks time.
Study NCT06509724 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated IMRT
Description: * Dose: 1.8-2.0 Gy per session, total 25-28 sessions (40-50.4Gy)~* Chemotherapy: Weekly, total 5-6 sessions
Study NCT06509724 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated IMRT
Description: * Dose: 2.5 Gy per session, total 16 sessions (40Gy)~* Chemotherapy: Weekly, total 3 sessions
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Description: Rifampicin 35 mg/kg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Isoniazid 10 or15 mg/kg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid (LZD)
Description: 1200 mg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Description: 25 mg/kg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide (PZA)
Description: 25 mg/kg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethambutol (EMB)
Description: 20 mg/kg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: 10 mg/kg
Study NCT05383742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 5 mg/kg
Study NCT06344091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
Study NCT05493410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TREATMENT GROUP (TG)
Description: In addition to muscle strengthening and aerobic exercise, patients from the TG will undergo IMT for six weeks, performing two sets of 30 repetitions daily using the device POWERbreathe classic medic® (POWERbreathe International Ltd., Southam, United Kingdom). MIP will be measured in all patients before the intervention as described earlier, and patients will exercise at 40% MIP in the first week and 60% MIP in the subsequent five weeks. The patients will be instructed to inhale using the diaphragm muscle, trying to expand the rib cage to avoid using accessory muscles A nose clip will be used to ensure patients breathe exclusively through the training device.
Study NCT05493410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP (CG)
Description: For six weeks the CG will perform muscle strengthening through a sit and stand up from a chair routine, abduction of upper and lower limbs, and rowing; three sets of 10 repetitions of each exercise will be performed. Elastic tubes will be used, with elasticity defined by color and indicating the greatest resistance the participant can endure with an effort between 4 and 8 on the OMNI-RES scale for perceived exertion.~In addition, aerobic exercise will be performed, through walking on flat terrain for five minutes in the first week, 10 minutes in the second week, and 20 minutes in the subsequent week, with intensity between 40-60% of the reserve heart rate and respecting the patients' symptoms.~Aerobic training intensity will be calculated by the modified BORG exertion scale maintaining a score between 6 and 7 - with the progression respecting the patients' symptoms - and by the reserve heart rate.
Study NCT06553430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobics exercises
Description: Moderate-intensity aerobic exercise for 30-60 min 3 times per week for 12 weeks
Study NCT04930783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: Administered as an injection given underneath the skin
Study NCT04930783 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEOVAX
Description: Personalized neoantigen vaccine administered as an injection given underneath the skin
Study NCT06311786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BIIB091
Description: Administered as specified in the treatment arm.
Study NCT04926142 — intervention group
Intervention type: DEVICE
Intervention: Implantation of Holter device
Description: Implantation of a Holter device (Reveal Linq, Medtronic) for telemonitoring of cardiac rhythm
Study NCT04926142 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous PFO closure
Description: Patients will undergo percutaneous closure of patent foramen ovale
Study NCT04930783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously (IV)
Study NCT04930783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously (IV)
Study NCT04892121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention exercises
Description: Participants will have to follow a warm-up prevention program (15 minutes) twice a week
Study NCT05253638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor
Description: Assessment of disease activity: This assessment will be performed using the systemic lupus erythematosus disease activity index (SLEDAI). The SLEDAI is an index designed to assess disease activity in the preceding 10 days, with 24 weighted clinical and laboratory variables corresponding to 9 different organs/systems. The SLEDAI score ranges from 0 to 105 Renal activity will be evaluated with the renal-SLEDAI (rSLEDAI), which represents the sum of the renal items of the SLEDAI. The rSLEDAI includes the following items: proteinuria, pyuria, erythrocyturia, and urine casts; each one is scored with 0 meaning absence or 4 points meaning presence; therefore, the maximum rSLEDAI is 16
Study NCT05113459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
Description: disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
Study NCT05018117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum
Study NCT05410054 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: observational research
Study NCT05018117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gum
Description: The effects of over-the-counter nicotine gum will be compared to a placebo gum
Study NCT06171061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxinshi tablet
Description: In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
Study NCT05852795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-mediated Mindfulness-Based Interventions
Description: The Experimental will undergo 8 weekly sessions of immersive experience lasting 30 minutes. Each session is divided as follows:~* First phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~* Second phase: Detection of physiological parameters with Oculus instrumentation turned ON during mindfulness experience (10 minutes~* Third phase: Detection of physiological parameters with Oculus equipment switched off (10 minutes).~This intervention will produce a multisensory experience merging visual and digital auditory stimuli. The audio recording also included some ambient natural sound effects, to make the practice more immersive.